Dual Clinical Efficacy of NLX-112 in Parkinson’s Disease Presented at Scientific Meetings

Ground-breaking Non-Dopaminergic Drug Combining Both Anti-Dyskinetic and Anti-Parkinsonian Properties

NJ, USA, August 22, 2023 /⁨EINPresswire.com⁩/ — Neurolixis, Inc., a private, clinical-stage company developing innovative drug therapies for the …Ground-breaking Non-Dopaminergic Drug Combining Both Anti-Dyskinetic and Anti-Parkinsonian Properties

NJ, USA, August 22, 2023 /⁨EINPresswire.com⁩/ — Neurolixis, Inc., a private, clinical-stage company developing innovative drug therapies for the …